In the ITT population, second-line treatment with osimertinib for EGFR T790M advanced NSCLC was associated with an improvement of 0.43 QALYs and incremental $67,588 costs compared with platinum-pemetrexed in the United States, resulting in an ICER of $159,126/QALYs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.